FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohn\u2019s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first approved oral product available to treat moderately to severely active Crohn\u2019s disease. Crohn’s disease is a chronic inflammatory bowel disease that causes inflammation in the digestive tract. It can affect any part of your digestive tract, and usually affects the small intestine and the beginning of the large intestine.<\/p>\n
Upadacitinib is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and axial spondyloarthritis.<\/p>\n
If RINVOQ (upadacitinib) tablets<\/strong> n<\/strong> are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong><\/em> RINVOQ is a prescription medicine used to treat:\u00a0Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated<\/b>.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"RINVOQ (upadacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2019<\/h2>\n